Queensland researchers have shown it is possible to genetically engineer a cellular safety switch to make T-cell transplantation therapy safer in patients with haematological malignancies. Scientists at the QIMR Berghofer Medical Research Institute have completed a phase I clinical trial using T-cells that have been manufactured to include the caspase 9 (iCasp9) cellular ‘switch’ that ...
QIMR researchers trial T-cell therapy with a ‘safety switch’ in blood cancers
By Michael Woodhead
19 Feb 2019